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Received 21 November 2012; accepted 22 November 2012Dengue has become a globally important mosquito-borne
infectious disease. It is estimated that more than 50 million
of people are affected by dengue every year. Although
dengue is not considered endemic in Taiwan, several
outbreaks have occurred, especially in southern Taiwan, in
the past decades.1 The most recent dengue epidemic in
2012 also involved more than 1000 cases by mid-November
in Tainan (>650 cases) and Kaohsiung cities (>350 cases) of
southern Taiwan.
Dengue virus infection causes a broad spectrum of
disease ranging from mild or dengue fever (DF) to severe or
dengue hemorrhagic fever (DHF). The progression from
mild DF to severe DHF and dengue shock syndrome (DSS) is
not predictable and current treatment is with supportive
fluid resuscitation. Major global efforts on mosquito control
for preventing dengue infection are so far expensive and
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clinical trials.
Dengue is a systemic arthropod-borne viral disease of
major global public health concern. Enhancing knowledge,
attitudes, and practice among primary healthcare profes-
sionals (HCPs) dealing with dengue will safeguard against
alarm and improve dengue therapy and control. Intensi-
fying medical/nursing education to strengthen familiarity
with important clinical features of dengue disease in HCPs
will also translate to greater benefits in dengue
management.2
DHF and DSS are particularly characterized by throm-
bocytopenia and plasma leakage. The roles of the host
immune system, particularly antibodies and leukocytes in
the manifestation of these symptoms in dengue infection,
have been a major focus of interest. The mechanisms of
pathogenesis in DHF/DSS include overproduction of proin-
flammatory cytokines, aberrant immune activation, and
antibody-dependent enhancement (ADE). Generally, anti-
bodies protect the host against most viral infections in
various ways, including neutralization of viruses, lysing
infected cells, and opsonization. Halstead3 originally
proposed ADE as an important pathogenic mechanism in
severe dengue disease, whereby preexisting antibodies
from a previous dengue virus infection may enhance& Formosan Medical Association. All rights reserved.
2 T.-S. Ho et al.heterotypic dengue virus infection of macrophages through
Fcg receptors. ADE increases the efficiency of virus infec-
tion and may suppress type I interferon (IFN)-mediated
antiviral responses. Aberrant activation of T cells and
overproduction of soluble factors by T cells and Fcg
receptor-bearing monocytes contribute to an increase in
vascular permeability.
Molecular mimicry is also a potential factor in dengue
virus pathogenesis. Molecular mimicry exists between
dengue virus proteins prM, E, and NS1 and self- proteins
such as protein disulfide isomerase, vimentin, heat shock
protein 60, coagulatory factors, plasminogen, thrombin,
and tissue plasminogen activator on platelets and endo-
thelial cells.4 An autoantibody-associated immunopatho-
genesis for dengue disease has been proposed5 in which
dengue virus infection induces autoreactive antiplatelet
and antiendothelial cell antibodies. These autoantibodies,
together with IFN-g activated macrophages may act to
phagocytose autoantibody-opsonized platelet and endo-
thelial cells. Such responses may contribute to vascular
endothelial leakage and/or thrombocytopenia in DHF/DSS.
Furthermore, molecular mimicry between prM/E/NS1 and
self-antigens raises concerns about the safety of dengue
virus vaccines.
In this issue of the Journal, Wan et al6 extend their
studies of autoreactive antibodies in dengue disease.
Dengue virus-induced autoantibodies against endothelial
cells, platelets, and coagulatory molecules may lead to
their abnormal activation or dysfunction. Recently gained
insights into the identity of cross-reactive epitopes as well
as the biologic consequences of dengue-induced autoanti-
bodies provide a fuller picture of the complexities of
dengue-associated immunopathology and vaccine
strategies.
Also in this issue of the Journal, Chuang et al7 provide
insight into the role of antibodies in coagulopathy in dengue
disease. Cytokines, complement, and dengue viral proteins
may all contribute hemostatic defects in dengue infection.
The combination of direct viral effects and indirect host
immunologic responses may tilt the balance of coagulation
and fibrinolysis toward bleeding in patients with DHF/DSS.In a recent Phase 2b clinical trial of a recombinant, live-
attenuated, CYD tetravalent dengue vaccine, the high
geometric mean titers of neutralizing antidengue anti-
bodies were not associated with high protective efficacy,8
a finding that implies that the role of antibodies in
dengue pathogenesis warrant further clarification. In the
meantime, several other vaccine candidates are also under
development. For the safety and efficacy of dengue vaccine
development, the immunopathogenic complications of
dengue disease need to be considered. Most importantly,
there is a need for enhanced collaborations between clin-
ical and basic researchers to improve integration of new
diagnostic agents, vaccines, and therapeutic agents for
dengue disease.References
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